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Background:  Regadenoson is a selective adenosine A2a receptor agonist, now being used extensively for radionuclide myocardial perfusion 
imaging (MPI). Patients with reactive airway disease are at an increased risk for adenosine induced bronchoconstriction via stimulation of A2b and 
A3 receptors.
Methods:  All patients who underwent radionuclide MPI using regadenoson stress test over a period of one year at our institution were included 
in this study. Patient demographics, past medical history including medications, hemodynamic data and the development of symptoms during the 
test were collected. The use of aminophylline to counter the effects of regadenoson in symptomatic patients was also recorded. Patients with chronic 
obstructive pulmonary disease (COPD) or asthma were compared to patients without COPD/asthma (control) using the above variables.
results:  The study included 799 patients with a mean age of 61±13 years. Out of the total cohort, 151(19%) had COPD/asthma with a mean 
age of 59+12 years and 32% were men. Patients with COPD/asthma had a higher incidence of shortness of breath (29.8% vs 18.2%; p = 0.0015) 
and headache (16.5% vs. 8.9%; p = 0.0058) when compared to the control group. However, no patients developed active wheezing during the test. 
Symptoms of chest discomfort, dizziness, gastrointestinal discomfort, nausea or arrhythmias were not significantly different between the groups. 
The use of aminophylline was significantly higher among COPD/asthma patients as compared to the control group (26.4% vs. 19.1%, p = 0.043). 
Changes in systolic blood pressure, diastolic blood pressure and heart rate response to regadenoson bolus were similar between the groups. There 
were no hemodynamically significant arrhythmias or serious adverse events in either group.
conclusions:  Patients with COPD/asthma undergoing regadenoson MPI had a higher incidence of shortness of breath and headache resulting in 
an increased use of aminophylline. Regadenoson was hemodynamically well tolerated without any serious adverse events in COPD/asthma patients.
